# High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

> **NCT07223385** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cedars-Sinai Medical Center** · enrollment: 80 (estimated)

## Conditions studied

- Prostate Cancer (Diagnosis)
- Prostate Cancer Stage IV
- CV Risk

## Interventions

- **OTHER:** Cardio-Oncology Referral
- **OTHER:** Notification to PCP/General Cardiologist

## Key facts

- **NCT ID:** NCT07223385
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-06
- **Final completion:** 2030-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223385, "High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07223385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*